TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14743119

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia with 12-15 ml of ropivacaine 0.75% and fentanyl 5 microg/ml followed by light general anesthesia and postoperative epidural analgesia with ropivacaine 0.2% and fentanyl 2 mg/ml
Number of subjects: 25

Group type: COMPARATOR
Intervention: Inhalatory or intravenous general anesthesia and intravenous tramadol postoperative analgesia
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: EPI-GEN group
Number of subjects: 25
Study: 11078493

Group type: EXPERIMENTAL
Intervention: 4‐HPR (200 mg/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8749970

Group type: EXPERIMENTAL
Intervention: Parental presence during venipuncture
Number of subjects: 130

Group type: COMPARATOR
Intervention: Parents absent during venipuncture
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Health professional performing venipuncture
Number of subjects: 130
Study: 1532970

Group type: EXPERIMENTAL
Intervention: Captopril therapy
Number of subjects: 52

Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Patients selected for late enlargement (n = 19)
Number of subjects: 52
Study: 3926862

Group type: EXPERIMENTAL
Intervention: Gluten-free diet
Number of subjects: 13

Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 13
Study: 29325593

Group type: EXPERIMENTAL
Intervention: Fostering Changes programme (12-week group-based training)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 237
Study: 27049107

Group type: EXPERIMENTAL
Intervention: 9 mg sodium hyaluronate plus saline solution
Number of subjects: 48

Group type: COMPARATOR
Intervention: Saline alone
Number of subjects: 48
Study: 24885889

Group type: EXPERIMENTAL
Intervention: Modern neuroscience approach (pain neuroscience education followed by cognition-targeted motor control training)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual care physiotherapy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Modern neuroscience approach
Number of subjects: 120
Study: 22664486

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy with an implantable defibrillator (CRT-D)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Quality of life (QOL) assessment using the Minnesota Living with Heart Failure questionnaire
Number of subjects: 80
Study: 20488825

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/day)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 18759963

Group type: EXPERIMENTAL
Intervention: Combined anticoagulation with unfractioned heparin (UFH) and tirofiban
Number of subjects: 40

Group type: COMPARATOR
Intervention: Unfractioned heparin (UFH)
Number of subjects: 40
Study: 16157415

Group type: EXPERIMENTAL
Intervention: Token reinforcement for eating fruits
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Token reinforcement for eating vegetables
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Token reinforcement for eating fruits and vegetables
Number of subjects: 188
Study: 12149235

Group type: EXPERIMENTAL
Intervention: G‐CSF‐mobilized peripheral blood hematopoietic stem cell transplantation (PBHSCT)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Bone marrow transplantation (BMT)
Number of subjects: 51
Study: 9952152

Group type: EXPERIMENTAL
Intervention: Midazolam (100 microg/kg) administered as a rapid intravenous bolus dose every 4-6 hours
Number of subjects: 60
Study: 7593731

Group type: EXPERIMENTAL
Intervention: Moclobemide 300 to 450 mg daily
Number of subjects: 0
Study: 2406656

Group type: EXPERIMENTAL
Intervention: Prenatal interventions provided by nurse‐midwives and nurses under their supervision
Number of subjects: 1458

Group type: COMPARATOR
Intervention: Standard high‐risk prenatal care provided by obstetricians
Number of subjects: 1458
Study: 6275495

Group type: EXPERIMENTAL
Intervention: Repeated colonoscopy 3 months after polypectomy in 80 patients
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: Repeated colorectal examinations every 6 months for patients with sessile villous adenomas, carcinoma in situ, and mucosal carcinoma
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: Repeated colorectal examinations every 6 months for patients with stalked polyps
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: Colonoscopy within 3 months of radical surgery for colorectal cancer
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: Follow-up after 12 months
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 629
Study: 30452422

Group type: EXPERIMENTAL
Intervention: Edasalonexent (33 mg/kg/day)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Edasalonexent (67 mg/kg/day)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Edasalonexent (100 mg/kg/day)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Edasalonexent (all doses)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Edasalonexent (after 7 days of dosing)
Number of subjects: 17
Study: 28840637

Group type: EXPERIMENTAL
Intervention: Cilnidipine 10 mg
Number of subjects: 74

Group type: COMPARATOR
Intervention: Amlodipine 5 mg
Number of subjects: 74
Study: 26901913

Group type: EXPERIMENTAL
Intervention: St‐Jude Trifecta stented prosthesis
Number of subjects: 40

Group type: COMPARATOR
Intervention: Medtronic Freestyle stentless prosthesis
Number of subjects: 40
Study: 23329538

Group type: EXPERIMENTAL
Intervention: Titanium plasma-sprayed cup with hydroxyapatite coating
Number of subjects: 42

Group type: COMPARATOR
Intervention: Titanium plasma-sprayed cup without hydroxyapatite coating
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both groups (with and without hydroxyapatite coating)
Number of subjects: 42
Study: 21539882

Group type: EXPERIMENTAL
Intervention: 1 dose of PCV
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 2 doses of PCV
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 3 doses of PCV
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 23vPPS booster at 12 months
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: mPPS at 17 months
Number of subjects: 8

Group type: COMPARATOR
Intervention: 0 doses of PCV
Number of subjects: 8
Study: 19388864

Group type: EXPERIMENTAL
Intervention: D&G combination (3 g)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (6 capsules)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Open-label D&G (1.5 g/day for 6 months)
Number of subjects: 100
Study: 17924300

Group type: EXPERIMENTAL
Intervention: STW 5
Number of subjects: 961

Group type: COMPARATOR
Intervention: MCP
Number of subjects: 961
Study: 15303765

Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 47

Group type: COMPARATOR
Intervention: Sodium nitroprusside
Number of subjects: 47
Study: 11319645

Group type: EXPERIMENTAL
Intervention: High-fat diet (41.4+/‐1.4 en% fat)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low-fat diet (17+/‐0.9 en% of fat)
Number of subjects: 10
Study: 9713664

Group type: EXPERIMENTAL
Intervention: Brief physician counseling plus follow-up
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 24
Study: 7994025

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN)
Number of subjects: 513

Group type: COMPARATOR
Intervention: Busulfan
Number of subjects: 513

Group type: COMPARATOR
Intervention: Hydroxyurea (HU)
Number of subjects: 513
Study: 2898268

Group type: EXPERIMENTAL
Intervention: BRL 26830A, 200 mg daily for two weeks then 400 mg daily for 18 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo for 18 weeks
Number of subjects: 40
Study: 30347431

Group type: EXPERIMENTAL
Intervention: Verubecestat (MK-8931) 20 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Verubecestat (MK-8931) 100 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Verubecestat (MK-8931) 450 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Verubecestat (MK-8931) 80 mg once daily for 14 days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Verubecestat (MK-8931) 150 mg once daily for 14 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 28399935

Group type: EXPERIMENTAL
Intervention: Conventional therapy with VR training
Number of subjects: 224

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 224
Study: 25794299

Group type: EXPERIMENTAL
Intervention: Low dose methylphenidate (up to 5mg×3) for 4 weeks
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Normal dose methylphenidate (up to 20mg×3) for 4 weeks
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Methylphenidate (60mg/day spread over three doses)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control (no medication for 4 weeks)
Number of subjects: 51
Study: 23211647

Group type: EXPERIMENTAL
Intervention: FVFP supplement (fruit plus vegetable concentrate, fish oil and probiotics)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: FVFP supplement
Number of subjects: 192
Study: 21477682

Group type: EXPERIMENTAL
Intervention: Mifepristone+misoprostol (200 mg mifepristone and 800 mcg buccal misoprostol 24 h later)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Misoprostol-only (800 mcg buccal misoprostol 24 h apart)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Misoprostol-only
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Mifepristone+misoprostol
Number of subjects: 400
Study: 20133265

Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV)
Number of subjects: 86
Study: 16421418

Group type: EXPERIMENTAL
Intervention: Dose-Intensive Epirubicin and Cyclophosphamide (DI-EC)
Number of subjects: 344

Group type: COMPARATOR
Intervention: Standard-Dose Anthracycline-Based Chemotherapy (SD-CT)
Number of subjects: 344
Study: 15204429

Group type: EXPERIMENTAL
Intervention: NH4Cl loading
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 11450724

Group type: EXPERIMENTAL
Intervention: Silicone canalicular plugs
Number of subjects: 44

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 44
Study: 9589647

Group type: COMPARATOR
Intervention: rhLH 0 IU/day
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: rhLH 25 IU/day
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: rhLH 75 IU/day
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: rhLH 225 IU/day
Number of subjects: 38
Study: 7999526

Group type: EXPERIMENTAL
Intervention: Migraine patients
Number of subjects: 152

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 152
Study: 3072307

Group type: EXPERIMENTAL
Intervention: Multivitamin preparation for 12 days
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 31656978

Group type: EXPERIMENTAL
Intervention: Diet with 33% de-oiled rice bran (DORB)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Diet with 38% de-oiled rice bran (DORB)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Diet with 43% de-oiled rice bran (DORB)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Diet with 53% de-oiled rice bran (DORB)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Diet with 58% de-oiled rice bran (DORB)
Number of subjects: 180
Study: 29427691

Group type: EXPERIMENTAL
Intervention: Wholemeal pasta (117g)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Refined wheat pasta (100g)
Number of subjects: 14
Study: 28626756

Group type: EXPERIMENTAL
Intervention: MyrLiq 400 mg/day
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: MyrLiq 200 mg/day
Number of subjects: 184

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study: 24330826

Group type: EXPERIMENTAL
Intervention: Agomelatine (25 mg/day p.o.) with immediate substitution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Agomelatine (25 mg/day p.o.) with short-tapering of previous drug
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Agomelatine (25 mg/day p.o.) with long-tapering of previous drug
Number of subjects: 0
Study: 22801472

Group type: EXPERIMENTAL
Intervention: Group C (3 hours of arm training per day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Group A (1 hour of arm training per day)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Group B (2 hours of arm training per day)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 32
Study: 21365213

Group type: EXPERIMENTAL
Intervention: Transoral robotic surgery (TORS)
Number of subjects: 24
Study: 18441708

Group type: EXPERIMENTAL
Intervention: monopril + propranolol + heparin
Number of subjects: 50

Group type: COMPARATOR
Intervention: propranolol + heparin
Number of subjects: 50
Study: 12612990

Group type: EXPERIMENTAL
Intervention: Standard oral nutritional supplement 2 hours before lunch
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo drink 30 minutes before lunch
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Standard oral nutritional supplement 30 minutes before lunch
Number of subjects: 13
Study: 9923328

Group type: EXPERIMENTAL
Intervention: Therapeutic touch
Number of subjects: 82

Group type: COMPARATOR
Intervention: Progressive muscle relaxation
Number of subjects: 82
Study: 7899060

Group type: EXPERIMENTAL
Intervention: Enhanced MRI (superparamagnetic iron oxide); pulse sequences: SE 500/20 (T1WI), SE 2000/20 (PDWI), SE 2000/70 (T2WI); contrast medium dose: 10 mumoles Fe/kg, administered intravenously for more than 30 minutes.
Number of subjects: 17

Group type: COMPARATOR
Intervention: Unenhanced MRI; pulse sequences: SE 500/20 (T1WI), SE 2000/20 (PDWI), SE 2000/70 (T2WI).
Number of subjects: 17

Group type: COMPARATOR
Intervention: Helical CT.
Number of subjects: 17
Study: 2559272

Group type: EXPERIMENTAL
Intervention: DTC 200 mg/m2 intravenously weekly for 16 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: No therapy (control)
Number of subjects: 40
Study: 352709

Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Chlorpromazine 25 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31507293

Group type: EXPERIMENTAL
Intervention: Balanced, implementer, optimizer, and random assignment team formation methods
Number of subjects: 237
Study: 28251894

Group type: EXPERIMENTAL
Intervention: Dermocosmetic treatment (containing lipohydroxyacid, nicotinamide, and piroctone-olamine)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 25712456

Group type: EXPERIMENTAL
Intervention: FOLFOXIRI plus bevacizumab (bev)
Number of subjects: 0

Group type: COMPARATOR
Intervention: FOLFIRI plus bevacizumab (bev)
Number of subjects: 0
Study: 23474581

Group type: EXPERIMENTAL
Intervention: Rotary technique (Group A)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Hybrid technique (Group B)
Number of subjects: 216
Study: 21099447

Group type: EXPERIMENTAL
Intervention: Maternal ω‐3 fatty acid supplementation (1.6 g eicosapentaenoic acid and 1.1 g docosahexaenoic acid)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maternal ω‐3 fatty acid supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19221150

Group type: EXPERIMENTAL
Intervention: First-line chemotherapy with prophylactic cranial irradiation
Number of subjects: 8779

Group type: COMPARATOR
Intervention: First-line chemotherapy without prophylactic cranial irradiation
Number of subjects: 8779
Study: 16754835

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 110

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 110
Study: 15016252

Group type: EXPERIMENTAL
Intervention: AmF/SnF(2)-containing toothpaste and mouthrinse
Number of subjects: 96
Study: 11699054

Group type: EXPERIMENTAL
Intervention: Cirrhosis patients (n = 38)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Controls with normal liver function (n = 29)
Number of subjects: 38
Study: 9174558

Group type: EXPERIMENTAL
Intervention: Heparin (5000 IU bd)
Number of subjects: 19435

Group type: EXPERIMENTAL
Intervention: Heparin (12,500 IU bd)
Number of subjects: 19435

Group type: EXPERIMENTAL
Intervention: Aspirin (300 mg daily)
Number of subjects: 19435

Group type: COMPARATOR
Intervention: No aspirin
Number of subjects: 19435
Study: 8198237

Group type: EXPERIMENTAL
Intervention: Open challenge with food additives (coloring agents, preservatives, citric acid, flavoring agents) using carbonated lemonade; two doses: low dose and 10-fold higher dose.
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Double-blind challenge with food additives (preservatives, coloring agents, citric acid) using gelatin capsules.
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Children with atopic skin symptoms (asthma, atopic dermatitis, rhinitis, urticaria).
Number of subjects: 335
Study: 29609646

Group type: EXPERIMENTAL
Intervention: Stereotactic body-radiotherapy (SBRT) boost dose of 18 Gy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stereotactic body-radiotherapy (SBRT) boost dose of 21 Gy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stereotactic body-radiotherapy (SBRT) boost (both doses)
Number of subjects: 0
Study: 26671303

Group type: EXPERIMENTAL
Intervention: Laparoscopic hysterectomy
Number of subjects: 292

Group type: COMPARATOR
Intervention: Total abdominal hysterectomy
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 292
Study: 23857438

Group type: EXPERIMENTAL
Intervention: CVC positioned in the right atrium (group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: CVC positioned in the superior vena cava (group C)
Number of subjects: 60
Study: 22784661

Group type: EXPERIMENTAL
Intervention: Problem Solving Technique applied by nurses (four-session protocol)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Usual care provided to caregivers
Number of subjects: 122
Study: 20135172

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy and common bile duct exploration at the same sitting
Number of subjects: 30

Group type: COMPARATOR
Intervention: Endoscopic stone clearance followed by laparoscopic cholecystectomy 4‐6 weeks later
Number of subjects: 30
Study: 19672410

Group type: EXPERIMENTAL
Intervention: Concentrated ambient particles (CAPs) + O(3)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Concentrated ambient particles (CAPs)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Filtered air (FA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: O(3)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Combined CAPs and O(3)
Number of subjects: 50
Study: 16373066

Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (MPH)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study: 12723011

Group type: EXPERIMENTAL
Intervention: Personalized follow-up intervention (including reminder letters and phone calls if no appointment was made within 10 days)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Standard follow-up intervention (reminder letters only)
Number of subjects: 132
Study: 10985216

Group type: EXPERIMENTAL
Intervention: bactrim
Number of subjects: 0

Group type: COMPARATOR
Intervention: aerosolized pentamidine (AP)
Number of subjects: 0
Study: 9120932

Group type: EXPERIMENTAL
Intervention: Oral antiandrogen (nilutamide)
Number of subjects: 868

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 868
Study: 8312689

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 3714619

Group type: EXPERIMENTAL
Intervention: Combined alpha- and beta-blockade (labetalol)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Beta-blockade alone (propranolol)
Number of subjects: 10
Study: 30157955

Group type: EXPERIMENTAL
Intervention: PSV + sigh
Number of subjects: 129

Group type: COMPARATOR
Intervention: Standard PSV
Number of subjects: 129
Study: 27586458

Group type: EXPERIMENTAL
Intervention: Community Health Agents (WAJA)
Number of subjects: 30
Study: 25083601

Group type: EXPERIMENTAL
Intervention: START (manualised coping skills intervention)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 260
Study: 22055330

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs) for 8 weeks
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Standard treatment plus SSRIs
Number of subjects: 90
Study: 19896202

Group type: EXPERIMENTAL
Intervention: Online LCM (Life Chart Methodology)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard paper LCM
Number of subjects: 48
Study: 18380940

Group type: EXPERIMENTAL
Intervention: Vaccination (twice before surgery or conservative treatment)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-vaccinated surgical patients
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Vaccinated surgical patients
Number of subjects: 40
Study: 16034289

Group type: EXPERIMENTAL
Intervention: Shelter-based intervention including intensive outreach by a psychiatric social worker and availability of weekly psychiatrist visits
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 102
Study: 12464463

Group type: EXPERIMENTAL
Intervention: 14‐mg nicotine patch
Number of subjects: 29
Study: 10234601

Group type: EXPERIMENTAL
Intervention: Nonprescription ibuprofen (800 to 1200 mg/day for 1 to 10 days)
Number of subjects: 2187

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2187

Group type: EXPERIMENTAL
Intervention: Nonprescription ibuprofen
Number of subjects: 2187
Study: 7795325

Group type: EXPERIMENTAL
Intervention: Counseling format A (informed antibiotics are safe)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Counseling format B (informed antibiotics are safe and about theoretical risk of diarrhea)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Counseling format A
Number of subjects: 138

Group type: COMPARATOR
Intervention: Counseling format B
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 138
Study: 1674104

Group type: EXPERIMENTAL
Intervention: Beta-adrenergic-antagonist treatment (propranolol in 203 patients and nadolol in 83 patients)
Number of subjects: 589

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 589
Study: 6795245

Group type: COMPARATOR
Intervention: Haloperidol (mean dose, 3.1 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lithium carbonate (mean dose, 1150 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31751170

Group type: EXPERIMENTAL
Intervention: Personalized online weight loss intervention
Number of subjects: 15
Study: 28661822

Group type: EXPERIMENTAL
Intervention: Family-based treatment for substance abuse disorder
Number of subjects: 190